|
We offer a broad range of high performance Redistribution® assays for primary screening of large compound libraries. These assays are validated to run at high throughput in singlicate to identify novel compounds active at relevant therapeutic targets in a cellular context.
Our portfolio of all Redistribution® assays target major signal transduction pathways involved in oncology, inflammation, metabolic diseases, membrane trafficking, DNA damage and protein degradation and cover target classes such as GPCRs, nuclear receptors, transcription factors, and kinases.
Click here for a complete list of validated Redistribution® screening assays. With each Screening Redistribution® Assay you receive:
- A stable cell line expressing the molecular target of interest fused to EGFP
- The plasmid used to generate the stable cell line
- An optimized assay protocol
- A reference compound validation data set
- A target-specific Redistribution® license to cover use of the assay for the specific application
- A target-specific Aequoria victoria EGFP license to cover use of the assay
- Technical support for setting up the assay at your site
For primary screening purposes, we have available a product application that allows you to screen an unlimited number of test compound wells per year. For secondary screening, profiling, lead optimization, or other lower volume applications, it's possible to purchase the assay as a more economical product that allows you to screen up to 25,000 test compound wells per year.
To request more information please contact us at 
|
